The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

BACKGROUND: PD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Wang, Dongxu, Yang, Xu, Long, Junyu, Lin, Jianzhen, Mao, Jinzhu, Xie, Fucun, Wang, Yunchao, Wang, Yanyu, Xun, Ziyu, Bai, Yi, Yang, Xiaobo, Guan, Mei, Pan, Jie, Seery, Samuel, Sang, Xinting, Zhao, Haitao
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8071846/
https://ncbi.nlm.nih.gov/pubmed/33912461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.646979
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars